Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Aim: Evidence of the relationship between the polymorphism of the complement factor H (CFH) gene at position 402 (Y402H) and the response to the treatment of wet AMD is controversial. The aim of this study was to compare the functional and morphological 1-year evolution of patients with exudative AMD treated with antivascular endothelial growth factor (VEGF) drugs with the CFH Y402H polymorphism in the Brazilian population. Methods: Forty-six patients treated for wet AMD with bevacizumab or ranibizumab in a pro re nata regimen were included. The evolution of best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the number of injections over 1 year of follow-up were correlated with CFH genotypes. Results: The analysis of variance for the difference between the BCVA denoted as log MAR (logarithm of the minimum angle of resolution) values showed an improvement at 1 year when compared to baseline (p = 0.039). Profile contrast analysis showed that this difference was significant only in the group without the C allele (p = 0.049), without significance in patients presenting with the risk allele (p = 0.241). CRT showed a mean reduction at 1 year compared to baseline (p < 0.001). Significant differences in the profile contrast test were found in the group without the C allele (p < 0.001) and in patients with the risk allele (p = 0.002). No difference was found in the number of injections among the different groups (p = 0.787). Conclusions: The presence of the risk allele of the Y402H polymorphism in the CFH gene was related to a less favorable evolution over 1 year in this sample of the Brazilian population with exudative AMD who were being treated with anti-VEGF drugs. In agreement with similar previous studies, this study concludes that the CFH risk genotypes may affect the disease response to treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while a study in a Brazilian cohort saw less visual improvement in the CC allele group [42].”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [42]
Citations
Cites
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
SPAIDE, R. F., LAUD, K., FINE, H. F., KLANCNIK, J. M., MEYERLE, C. B., YANNUZZI, L. A., SORENSON, J., SLAKTER, J., FISHER, Y. L., & COONEY, M. J. (2006) · Retina · doi:10.1097/00006982-200604000-00001 · Cited by 630
Holz, F. G., Amoaku, W., Donate, J., Guymer, R. H., Kellner, U., Schlingemann, R. O., Weichselberger, A., & Staurenghi, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.019 · Cited by 413
Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration
Seddon, J. M., Francis, P. J., George, S., Schultz, D. W., Rosner, B., & Klein, M. L. (2007) · JAMA · doi:10.1001/jama.297.16.1793 · Cited by 330
Age‐related Macular Degeneration (AMD)
(2008) · Encyclopedia of Molecular Pharmacology · doi:10.1007/978-3-540-38918-7_5059 · Cited by 314
Racial differences in the prevalence of age-related macular degeneration
Friedman, D. S., Katz, J., Bressler, N. M., Rahmani, B., & Tielsch, J. M. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90267-1 · Cited by 304
Brown, D. M., & Regillo, C. D. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.06.039 · Cited by 224
Brantley, M. A., Fang, A. M., King, J. M., Tewari, A., Kymes, S. M., & Shiels, A. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.008 · Cited by 201
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration
Skerka, C., Lauer, N., Weinberger, A. A. W. A., Keilhauer, C. N., Sühnel, J., Smith, R., Schlötzer–Schrehardt, U., Fritsche, L., Heinen, S., & Hartmann, A. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.02.012 · Cited by 197
Risk factors for age-related macular degeneration: an update
Hyman, L., & Neborsky, R. (2002) · Current Opinion in Ophthalmology · doi:10.1097/00055735-200206000-00007 · Cited by 163
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., Kim, I. K., Klein, M. L., Maguire, M. G., & Martin, D. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.037 · Cited by 142
Lee, A. Y., Raya, A. K., Kymes, S. M., Shiels, A., & Brantley, M. A. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.150995 · Cited by 134
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD
Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6080 · Cited by 120
Seddon, J. M., Silver, R. E., Kwong, M., & Rosner, B. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.14-15841 · Cited by 100
Inflammation and the pathogenesis of age-related macular degeneration
Augustin, A. J., & Kirchhof, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902942322 · Cited by 95
Nischler, C., Oberkofler, H., Ortner, C., Paikl, D., Riha, W., Lang, N., Patsch, W., & Egger, S. F. (2011) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2010.02080.x · Cited by 81
Orlin, A., Hadley, D., Chang, W., Ho, A. C., Brown, G., Kaiser, R. S., Regillo, C. D., Godshalk, A. N., Lier, A., Kaderli, B., et al. (2012) · Retina · doi:10.1097/iae.0b013e31822a2c7c · Cited by 60
(2011) · Europe PMC (PubMed Central) · Cited by 55
Tian, J., Qin, X., Fang, K., Chen, Q., Hou, J., Li, J., Yu, W., Chen, D., Hu, Y., & Li, X. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.53 · Cited by 47
Gangnon, R. E., Lee, K. E., Klein, R., Iyengar, S. K., Sivakumaran, T. A., & Klein, R. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2012.693 · Cited by 44
Yıldız, B. K., Özdek, Ş., Ergün, M. A., Ergün, S. G., Tuncay, F. Y., & Elbeğ, Ş. (2016) · Ophthalmic Research · doi:10.1159/000446186 · Cited by 24
Medina, F. M. C., da Motta, A. A. L., Takahashi, W. Y., Carricondo, P. C., Motta, M. M. D. S., de Melo, M. B., & de Vasconcellos, J. P. C. (2015) · Ophthalmic Research · doi:10.1159/000439172 · Cited by 19
Self-citationVeloso, C. E. D. R., de Almeida, L. N. F., & Nehemy, M. B. (2014) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-69912014006002 · Cited by 15
Cruz-González, F., Cabrillo-Estevez, L., Gutiérrez, V. R., Sanchez-Jara, A., de Juan-Marcos, L., & González‐Sarmiento, R. (2016) · International Journal of Ophthalmology · doi:10.18240/ijo.2016.09.12 · Cited by 15
Hirata, F. E., de Vasconcellos, J. P. C., Medina, F. M., Rim, P. H. H., Fulco, E. A. M., & de Melo, M. B. (2013) · Ophthalmic Genetics · doi:10.3109/13816810.2013.867449 · Cited by 13
Self-citationSacconi, D. P. D., de Vasconcellos, J. P. C., Hirata, F. E., Medina, F. M., Rim, P. H. H., & de Melo, M. B. (2016) · Ophthalmic Genetics · doi:10.3109/13816810.2015.1120315 · Cited by 4
Self-citation
Cited by
Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration
Lorés‐Motta, L., de Jong, E. K., & den Hollander, A. I. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0332-1 · Cited by 35
Biomarkers as Predictive Factors of Anti-VEGF Response
Bobadilla, M., Pariente, A., Ana, I., Peláez, R., Pérez-Sala, Á., & Larráyoz, I. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051003 · Cited by 33
Yan, Z., Shi, H., Zhu, R., Li, L., Qin, B., Kang, L., Chen, H., & Guan, H. (2018) · PubMed Central · Cited by 30
Kozhevnikova, O. S., Фурсова, А. Ж., Derbeneva, A. S., Nikulich, I. F., Сергеевич, Т. М., Devyatkin, V. A., Rumyantseva, Y. V., Telegina, D. V., & Kolosova, N. G. (2022) · Biomedicines · doi:10.3390/biomedicines10071658 · Cited by 17
“Individualized treatment is needed even more in developing countries due to the high cost of anti-VEGF therapy, in addition to the potential reduction of side effects for patients [45].”
BackgroundGorin, M. B., & daSilva, M. J. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107894 · Cited by 14
Metadata
- Authors
- Medina, F. M. C., Motta, A. A. L. D., Takahashi, W. Y., Carricondo, P. C., Motta, M. M. D. S., Melo, M. B., & Vasconcellos, J. P. C.
- Affiliations
- Universidade de São Paulo (BR)
- Venue
- Ophthalmic Research
- Publisher
- S. Karger AG
- Published
- 2017-06-23
- Volume
- 61
- Issue
- 3
- Pages
- 168-173
- ISSN
- 0030-3747 (ISSN-L)
- 1423-0259
- OpenAlex
- W2704667116
- Cited by
- 12
- References
- 27
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 4 · 2021: 1 · 2019: 2 · 2018: 3
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Ophthalmic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- complement factor H, CFH Y402H polymorphism, neovascular age-related macular degeneration, anti-VEGF therapy, bevacizumab, ranibizumab, treatment response, genetic susceptibility, best-corrected visual acuity, central retinal thickness, Brazilian population
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Alleles, Brazil, Female, Humans, Male, Pharmacogenetics, Retrospective Studies, Visual Acuity, Complement Factor H, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections, Genotyping Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.